Marina Biotech and Mirna Therapeutics this week announced that they have amended an existing licensing agreement to give Mirna greater access to Marina's Smarticle liposomal delivery technology for use with microRNA-based therapeutics.
In early 2012, the companies first inked their deal, which gave Mirna the right to use the delivery technology with its lead cancer candidate, the phase I miRNA mimic MRX34.
Under the terms of the amended arrangement, Mirna has made certain payments to Marina in exchange for additional undisclosed rights to the Smarticle technology as it relates to the MRX34 program. Further, Mirna has obtain the exclusive rights to the technology with "several" additional unnamed tumor-suppressor miRNA targets.
Additional details were not disclosed.